Delphiatx logo
  • About
  • Science
  • News
  • Careers
09/25/2023

ENDPOINTS: For decades, cancer drug developers have focused on inhibition. Now, a GV-backed startup is eyeing activation

Share

  • Share on LinkedIn
Delphiatx logo
  • About
  • Science
  • News
  • Careers

1400 One Kendall Square
Suite 14-302
Cambridge, MA 02139

Inquiries: contact@delphiatx.com
Media: katie@1abmedia.com

Copyright © 2025 Delphia Therapeutics

  • Privacy Policy
LinkedIn